significant problems are inherent in human blood transfusions.
First, there is an increasing shortage of donors which becomes more I ^ severe due^ to the rising incidence of AIDS carriers in bloodt/ v/y V Vk a donating populations (5). Second, red blood cells carry multiple antigenic determinants so that donor blood must be carefully typed ■ jjj&T* u and cross-matched before administration, a time-consuming and *UJ vJ^C OBtly process. Third, blood has a limited "shelf-life" due to short storage viability, which at the present does not exceed one month. Fourth, blood storage and distribution is logisticallydemanding because it must be stored and delivered at 4°C. Finally, blood can carry virally-transmitted diseases such as AIDS and hepatitis. Therefore, there is a profound clinical, economical and logistical demand for a non-antigenic, disease-free, easily transportable and long-term storable blood substitute.
The hemoglobin tetramer has been the leading candidate for
Buch a blood substitute because of its natural property to carry, deliver and release oxygen in a cooperative manner, its high saturation at ambient oxygen pressures, and its capacity to harbor as much as 1.39 ml of oxygen per gram protein. Indeed, three hemoglobin-based strategies are currently under development for use in patients with hemorrhagic shock: a) stroma-free hemoglobin (SFH), b) modified SFH, and c) liposome encapsulated hemoglobin (LEH).
The rationale for the production of SFH is to avoid the 
